Research Article

Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma

Volume: 45 Number: 2 June 30, 2024
EN TR

Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma

Abstract

Multiple myeloma is a hematological malignancy identified by bone marrow infiltration of clonal plasma cells. It is still not a curable disease under current conditions. Cathepsin G is a serine protease playing a role in inflammation that is present in the azurophilic granules of neutrophils. It is known that there is a relationship between Cathepsin G and chronic inflammatory diseases and tumors. The goal of the study is to define its role in multiple myeloma. In the study, 33 patients newly diagnosed with MM who were never received treatment and 33 control subjects were included. Basic laboratory parameters and Cathepsin G levels were examined both in the myeloma patient group and control group. While the serum CathG level in the control group is 22.84 ng/mL, the serum CathG level of the MM patient group is 10.77 ng/mL. Serum CathG level in the control group is statistically significantly higher than the MM patient group. The aim of the present study is to contribute to the literature in hematological malignancies, to figure out the role of Cathepsin G in multiple myeloma, and to open a door to new treatment options for multiple myeloma, which is an incurable disease, yet.

Keywords

Cathepsin G, Inflammation, Multiple myeloma

References

  1. [1] Rajkumar SV., Multiple myeloma: Every year a new standard?, Hematological oncology, 37 (2019) 62-65.
  2. [2] Zamolodchikova T.S., Tolpygo S.M., Svirshchevskaya E.V., Cathepsin G—not only inflammation: the immune protease can regulate normal physiological processes, Frontiers in immunology, 11 (2020) 411.
  3. [3] Wang J., Sjöberg S., Tang T.T., Oörni K., Wu W., Liu C., Secco B., Tia V., Sukhova G.K., Fernandes C., Lesner A., Kovanen P.T., Libby P., Cheng X., Shi G.P., Cathepsin G activity lowers plasma LDL and reduces atherosclerosis, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1842(11) (2014) 2174-2183.
  4. [4] Tazawa H., Okada F., Kobayashi T., Tada M., Mori Y., Une Y., Sendo F., Kobayashi M., Hosokawa M., Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression, American Journal of Pathology, 163(6) (2003) 2221– 2232.
  5. [5] Smith H.A., Kang Y., The metastasis-promoting roles of tumor-associated immune cells, J Mol Med., 91(4) (2013) 411–429.
  6. [6] Fridlender Z.G., Albelda S.M., Tumor associated neutrophils: friend or foe?, Carcinogenesis, 33(5) (2012) 949–955.
  7. [7] Pham C.T., Neutrophil serine proteases: specific regulators of inflammation, Nat Rev Immunol., 6(7) (2006) 541–550.
  8. [8] Martins-Cardoso K., Almeida V.H., Bagri K.M., Rossi M.I.D., Mermelstein C.S., König S., Monteiro R.Q., Neutrophil extracellular traps (Nets) promote pro-metastatic phenotype in human breast cancer cells through epithelial–mesenchymal transition, Cancers, 12(6) (2020) 1542.
  9. [9] Li Y., Yang Y., Gan T., Zhou J., Hu F., Hao N., Yuan B., Chen Y., Zhang M., Extracellular RNAs from lung cancer cells activate epithelial cells and induce neutrophil extracellular traps, International journal of oncology, 55(1) (2019) 69-80.
  10. [10] Shang A., Gu C., Zhou C., Yang Y., Chen C., Zeng B., Wu J., Lu W., Wang W., Sun Z., Li D., Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression, Cell Communication and Signaling, 18(1) (2020) 1-14.
APA
Terzi, H. (2024). Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma. Cumhuriyet Science Journal, 45(2), 263-267. https://doi.org/10.17776/csj.1453805
AMA
1.Terzi H. Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma. CSJ. 2024;45(2):263-267. doi:10.17776/csj.1453805
Chicago
Terzi, Hatice. 2024. “Determination of Serum Cathepsin G Level in Patients With Multiple Myeloma”. Cumhuriyet Science Journal 45 (2): 263-67. https://doi.org/10.17776/csj.1453805.
EndNote
Terzi H (June 1, 2024) Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma. Cumhuriyet Science Journal 45 2 263–267.
IEEE
[1]H. Terzi, “Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma”, CSJ, vol. 45, no. 2, pp. 263–267, June 2024, doi: 10.17776/csj.1453805.
ISNAD
Terzi, Hatice. “Determination of Serum Cathepsin G Level in Patients With Multiple Myeloma”. Cumhuriyet Science Journal 45/2 (June 1, 2024): 263-267. https://doi.org/10.17776/csj.1453805.
JAMA
1.Terzi H. Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma. CSJ. 2024;45:263–267.
MLA
Terzi, Hatice. “Determination of Serum Cathepsin G Level in Patients With Multiple Myeloma”. Cumhuriyet Science Journal, vol. 45, no. 2, June 2024, pp. 263-7, doi:10.17776/csj.1453805.
Vancouver
1.Hatice Terzi. Determination of Serum Cathepsin G Level in Patients with Multiple Myeloma. CSJ. 2024 Jun. 1;45(2):263-7. doi:10.17776/csj.1453805